Fig. 6: L¹⁰B-3 vesicles as targeted B-10 agents for BNCT combined Dox@vehicles in PANC-1 models radiochemotherapy.

a The biodistribution of Cy5.5@vesicles was monitored using the IVIS imaging system. b Following the intravenous injection of Cy5.5@vesicles, the biodistribution was assessed in major organs at 6 h. c Corresponding fluorescence intensities in major organs at 6 h post-intravenous injection. d B-10 content in the major organs for the group receiving vesicle doses of 350 mg/kg. e B-10 content in the major organs for the group receiving vesicle doses of 250 mg/kg. f The tumor/normal tissue ratio and tumor/blood ratio of B-10 content in the two dosage groups. g Schematic illustration of the experimental flow. h Quantification of incorporated radioactivity. i Subcutaneous tumor volume growth curves. j Overall survival estimated by Kaplan–Meier curves. k Tumor growth curves for individual mice. l Body weight curves of PANC-1 bearing mice in each experimental group. m Tumor growth curves after Dox@vesicles injection indicating recurrence. n Statistical analysis of body weight and o overall survival between BNCT alone and BNCT combined with Dox@vesicles over 15 days post-Dox@vesicles injection. Data are displayed as mean ± SD of n = 3 independent measurements in (c–f), n = 8 independent measurements in (h–l), and n = 5 independent measurements in (m–o). P values in (h) were determined by One-way ANOVA analysis followed by Tukey’s multiple comparisons test. n.s., not significant, *P < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.